Literature DB >> 27267386

cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors.

Graeme B Bolger1, Mariana F Bizzi2, Sergio V Pinheiro3, Giampaolo Trivellin4, Lisa Smoot5, Mary-Ann Accavitti6, Márta Korbonits4, Antonio Ribeiro-Oliveira2.   

Abstract

PDE4 cyclic nucleotide phosphodiesterases regulate cAMP abundance in cells and therefore regulate numerous processes, including cell growth and differentiation. The rat PDE4A5 isoform (human homolog PDE4A4) interacts with the AIP protein (also called XAP2 or ARA-9). Germline mutations in AIP occur in approximately 20% of patients with Familial Isolated Pituitary Adenoma (FIPA) and 20% of childhood-onset simplex somatotroph adenomas. We therefore examined the protein expression of PDE4A4 and the closely related isoform PDE4A8 in normal human pituitary tissue and in pituitary adenomas. PDE4A4 had low expression in normal pituitary but was significantly overexpressed in somatotroph, lactotroph, corticotroph and clinically nonfunctioning gonadotroph adenomas (P<0.0001 for all subtypes). Likewise, PDE4A8 was expressed in normal pituitary and was also significantly overexpressed in the adenoma subtypes (P<0.0001 for all). Among the different adenoma subtypes, corticotroph and lactotroph adenomas were the highest and lowest expressed for PDE4A4, respectively, whereas the opposite was observed for PDE4A8. Naturally occurring oncogenic variants in AIP were shown by a two-hybrid assay to disrupt the ability of AIP to interact with PDE4A5. A reverse two-hybrid screen identified numerous additional variants in the tetratricopeptide repeat (TPR) region of AIP that also disrupted its ability to interact with PDE4A5. The expression of PDE4A4 and PDE4A8 in normal pituitary, their increased expression in adenomatous pituitary cells where AIP is meant to participate, and the disruption of the PDE4A4-AIP interaction by AIP mutants may play a role in pituitary tumorigenesis.
© 2016 Society for Endocrinology.

Entities:  

Keywords:  AIP; FIPA; PDE4A4; PDE4A5; PDE4A8; PKA; cAMP; phosphodiesterases; pituitary adenomas

Mesh:

Substances:

Year:  2016        PMID: 27267386      PMCID: PMC4901527          DOI: 10.1530/ERC-15-0205

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  50 in total

Review 1.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

Review 2.  cAMP in the pituitary: an old messenger for multiple signals.

Authors:  Erika Peverelli; Giovanna Mantovani; Andrea G Lania; Anna Spada
Journal:  J Mol Endocrinol       Date:  2013-12-19       Impact factor: 5.098

Review 3.  Genetics of pituitary adenomas.

Authors:  Monica R Gadelha; Giampaolo Trivellin; Laura Cristina Hernández Ramírez; Márta Korbonits
Journal:  Front Horm Res       Date:  2013-03-19       Impact factor: 2.606

4.  PRKACB and Carney complex.

Authors:  Antonella Forlino; Annalisa Vetro; Livia Garavelli; Roberto Ciccone; Edra London; Constantine A Stratakis; Orsetta Zuffardi
Journal:  N Engl J Med       Date:  2014-02-26       Impact factor: 91.245

5.  Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibition.

Authors:  I McPhee; S J Yarwood; G Scotland; E Huston; M B Beard; A H Ross; E S Houslay; M D Houslay
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

6.  p62 (SQSTM1) and cyclic AMP phosphodiesterase-4A4 (PDE4A4) locate to a novel, reversible protein aggregate with links to autophagy and proteasome degradation pathways.

Authors:  Frank Christian; Diana F Anthony; Surakiran Vadrevu; Tracy Riddell; Jonathan P Day; Ruth McLeod; David R Adams; George S Baillie; Miles D Houslay
Journal:  Cell Signal       Date:  2010-06-19       Impact factor: 4.315

7.  Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation.

Authors:  Giampaolo Trivellin; Adrian F Daly; Fabio R Faucz; Bo Yuan; Liliya Rostomyan; Darwin O Larco; Marie Helene Schernthaner-Reiter; Eva Szarek; Letícia F Leal; Jean-Hubert Caberg; Emilie Castermans; Chiara Villa; Aggeliki Dimopoulos; Prashant Chittiboina; Paraskevi Xekouki; Nalini Shah; Daniel Metzger; Philippe A Lysy; Emanuele Ferrante; Natalia Strebkova; Nadia Mazerkina; Maria Chiara Zatelli; Maya Lodish; Anelia Horvath; Rodrigo Bertollo de Alexandre; Allison D Manning; Isaac Levy; Margaret F Keil; Maria de la Luz Sierra; Leonor Palmeira; Wouter Coppieters; Michel Georges; Luciana A Naves; Mauricette Jamar; Vincent Bours; T John Wu; Catherine S Choong; Jerome Bertherat; Philippe Chanson; Peter Kamenický; William E Farrell; Anne Barlier; Martha Quezado; Ivana Bjelobaba; Stanko S Stojilkovic; Jurgen Wess; Stefano Costanzi; Pengfei Liu; James R Lupski; Albert Beckers; Constantine A Stratakis
Journal:  N Engl J Med       Date:  2014-12-03       Impact factor: 91.245

Review 8.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

9.  The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability.

Authors:  Manuela Vargiolu; Daniela Fusco; Ivana Kurelac; Dietmar Dirnberger; Ralf Baumeister; Isabella Morra; Antonio Melcarne; Roberto Rimondini; Giovanni Romeo; Elena Bonora
Journal:  J Clin Endocrinol Metab       Date:  2009-04-14       Impact factor: 5.958

10.  An integrated map of genetic variation from 1,092 human genomes.

Authors:  Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

View more
  13 in total

1.  Prkar1a haploinsufficiency ameliorates the growth hormone excess phenotype in Aip-deficient mice.

Authors:  Marie Helene Schernthaner-Reiter; Giampaolo Trivellin; Thomas Roetzer; Johannes A Hainfellner; Matthew F Starost; Constantine A Stratakis
Journal:  Hum Mol Genet       Date:  2020-10-10       Impact factor: 6.150

2.  Pituitary corticotroph identity and receptor-mediated signaling: a transcriptomics perspective.

Authors:  Stanko S Stojilkovic; Rafael M Previde; Arthur S Sherman; Patrick A Fletcher
Journal:  Curr Opin Endocr Metab Res       Date:  2022-06-09

3.  Interaction of AIP with protein kinase A (cAMP-dependent protein kinase).

Authors:  Marie Helene Schernthaner-Reiter; Giampaolo Trivellin; Constantine A Stratakis
Journal:  Hum Mol Genet       Date:  2018-08-01       Impact factor: 6.150

Review 4.  Drug resistance in pituitary tumours: from cell membrane to intracellular signalling.

Authors:  Erika Peverelli; Donatella Treppiedi; Federica Mangili; Rosa Catalano; Anna Spada; Giovanna Mantovani
Journal:  Nat Rev Endocrinol       Date:  2021-06-30       Impact factor: 43.330

Review 5.  PDE4 subtypes in cancer.

Authors:  Samuel Hsien Lai; Guston Zervoudakis; Jesse Chou; Mark E Gurney; Kelly M Quesnelle
Journal:  Oncogene       Date:  2020-03-20       Impact factor: 9.867

Review 6.  The genetic background of acromegaly.

Authors:  Mônica R Gadelha; Leandro Kasuki; Márta Korbonits
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

7.  Multi-chaperone function modulation and association with cytoskeletal proteins are key features of the function of AIP in the pituitary gland.

Authors:  Laura C Hernández-Ramírez; Rhodri M L Morgan; Sayka Barry; Fulvio D'Acquisto; Chrisostomos Prodromou; Márta Korbonits
Journal:  Oncotarget       Date:  2018-01-11

8.  Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma.

Authors:  Federica Ragusa; Nadia Panera; Silvia Cardarelli; Marco Scarsella; Marzia Bianchi; Stefano Biagioni; Mauro Giorgi; Anna Alisi; Mara Massimi
Journal:  Cancers (Basel)       Date:  2021-05-01       Impact factor: 6.639

9.  AIP mutations in Brazilian patients with sporadic pituitary adenomas: a single-center evaluation.

Authors:  Paula Bruna Araujo; Leandro Kasuki; Carlos Henrique de Azeredo Lima; Liana Ogino; Aline H S Camacho; Leila Chimelli; Márta Korbonits; Monica R Gadelha
Journal:  Endocr Connect       Date:  2017-10-26       Impact factor: 3.335

Review 10.  Role of Phosphodiesterase in the Biology and Pathology of Diabetes.

Authors:  Agnieszka Kilanowska; Agnieszka Ziółkowska
Journal:  Int J Mol Sci       Date:  2020-11-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.